NLRP3 and breast cancer: Among small-molecule compounds with NLRP3 inhibitory activity, CY-09 increases gemcitabine sensitivity in triple-negative BC, limiting the activation of the EMT/IL-1β/Wnt/β-catenin signaling pathway [185].